| First Author | Shi L | Year | 2024 |
| Journal | J Mol Cell Cardiol | Volume | 188 |
| Pages | 38-51 | PubMed ID | 38224851 |
| Mgi Jnum | J:350116 | Mgi Id | MGI:7595350 |
| Doi | 10.1016/j.yjmcc.2024.01.002 | Citation | Shi L, et al. (2024) Downregulation of Wtap causes dilated cardiomyopathy and heart failure. J Mol Cell Cardiol 188:38-51 |
| abstractText | RNA binding proteins have been shown to regulate heart development and cardiac diseases. However, the detailed molecular mechanisms is not known. In this study, we identified Wilms' tumor 1-associating protein (WTAP, a key regulatory protein of the m(6)A RNA methyltransferase complex) as a key regulator of heart function and cardiac diseases. WTAP is associated with heart development, and its expression is downregulated in both human and mice with heart failure. Cardiomyocyte-specific knockout of Wtap (Wtap-CKO) induces dilated cardiomyopathy, heart failure and neonatal death. Although WTAP deficiency in the heart decreases METTL3 (methyltransferase-like 3) protein levels, cardiomyocyte-specific overexpression of Mettl3 in Wtap-CKO mice does not rescue the phenotypes of Wtap-CKO mice. Instead, WTAP deficiency in the heart decreases chromatin accessibility in the promoter regions of Mef2a (myocyte enhancer factor-2alpha) and Mef2c, leading to reduced mRNA and protein levels of these genes and lower expression of their target genes. Conversely, WTAP directly binds to the promoter of the Mef2c gene and increases its promoter luciferase activity and expression. These data demonstrate that WTAP plays a key role in heart development and cardiac function by maintaining the chromatin accessibility of cardiomyocyte specific genes. |
